| Name | Title | Contact Details |
|---|
Carman Oaks is a Lake Oswego, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our vision is to serve our communities’ evolving healthcare needs by cultivating a network of compassionate, dedicated professionals. We are committed to working together, using best practices, improving quality, and assuring an exceptional patient experience. Our highest priority is caring for people - the friends, family and neighbors whom we serve in our community. We are committed to providing an environment based on respect and one which encourages personal and profession growth.
North Mississippi Primary Health Care is a community health center operating in Northeast Mississippi for the past 25 years. They provide healthcare services to Benton, Marshall, Tippah, Prentiss, Union, Alcorn, and Tishomingo counties.
Arkansas-based Beverly (NYSE: BEV) operates 351 nursing homes, 18 assisted living centers and 52 hospice and home health centers.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.